San Antonio Breast Cancer Symposium | Conference

Dr. Hurvitz on neoMONARCH Trial for HR+ Breast Cancer

December 9th 2016

Sara A. Hurvitz, MD, medical oncologist, associate professor of Medicine, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, UCLA, discusses the findings of the neoMONARCH trial, a neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole, which induced a response rate of 54.7% in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Dr. Robertson on Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer

December 9th 2016

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.

Neoadjuvant Estrogen Attack Falters in High-Risk Breast Cancer Patients

December 9th 2016

An attempt to strengthen neoadjuvant treatment of patients with locally advanced HR-positive and HER2-positive breast cancer by adding estrogen deprivation therapy to a standard regimen failed to significantly improve response rates but did illustrate the extensive toxicity of the chemotherapy agents used in this setting.

Biomarker Analysis Shows Promise for Predicting Breast Cancer Response

December 9th 2016

A biomarker analysis of participants in a phase II breast cancer trial demonstrated potential for identifying tumor markers to predict susceptibility to specific therapies.

HER2-Enriched Breast Tumor Subtype Predicts Response to HER2 Dual Blockade

December 9th 2016

The HER2-enriched subtype of HER2-positive breast cancer is a strong predictor of sensitivity to dual HER2 blockade without the use of chemotherapy.

No Clinical Benefit With Adjuvant Ibandronate in Postmenopausal Breast Cancer

December 9th 2016

Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.

Neoadjuvant Abemaciclib Active in HR+/HER2- Breast Cancer

December 9th 2016

A neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole induced a response rate of 54.7% in patients with HR+/HER2-negative early-stage breast cancer, according to findings from the phase II neoMONARCH trial.

Hormonal Therapy Effectively Added to Dual HER2-Blockade in Phase II PERTAIN Study

December 8th 2016

The addition of an aromatase inhibitor (AI) to pertuzumab and trastuzumab improved progression-free survival by 3.09 months, when compared with trastuzumab plus an AI.

Buparlisib Combo Modestly Effective in Pretreated HR+ Breast Cancer

December 8th 2016

Median progression-free survival was improved by 2.1 months with the addition of the pan-PI3K inhibitor buparlisib to fulvestrant for women with HR-positive/HER2-negative advanced breast cancer who received a prior aromatase inhibitor and progressed on or after an mTOR inhibitor.

Dr. Lindeman on RANK Ligand as Breast Cancer Prevention Target in BRCA1 Carriers

December 8th 2016

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a study exploring RANK ligand as a target for breast cancer prevention in patients who harbor the BRCA1 mutation.

Dr. Kornblum on Impact of PrECOG 0102 Trial for HR+/HER2- Breast Cancer

December 8th 2016

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, and attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the phase II PrECOG 0102 trial, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Six Years of Anastrozole After Adjuvant Tamoxifen Not Better Than 3 Years

December 8th 2016

First results from the phase III DATA study show no advantage to extending anastrozole therapy from 3 years to 6 for the primary endpoint of 5-year adapted disease-free survival.

Mixed Results on Benefit of Extending Letrozole Beyond 5 Years of Prior Endocrine Therapy

December 8th 2016

Extending letrozole therapy in women with early-stage, HR-positive breast cancer who completed 5 years of prior hormone therapy did not yield a statistically significant improvement in either disease-free or overall survival, but prolonged use of the aromatase inhibitor may be beneficial in some subgroups of women with a higher risk of recurrence.

Genomic Study Uncovers Resistance Mutations in ER+ Breast Cancer

December 8th 2016

The genomic landscape of recurrent metastatic estrogen receptor–positive breast cancer differed significantly from the mutational profile of primary disease in a study that sheds light on acquired resistance mechanisms to anticancer therapies.

TILs Associated With Survival for Advanced HER2+ Breast Cancer

December 8th 2016

Higher levels of tumor-infiltrating lymphocytes were associated with improvements in overall survival for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab in the phase III CLEOPATRA trial.

Veliparib Regimen Nears 80% Response Rate in BRCA+ Breast Cancer

December 8th 2016

Adding the PARP inhibitor veliparib to carboplatin/paclitaxel chemotherapy induced a response rate of 77.8% in patients with advanced BRCA-positive breast cancer.

Everolimus Added to Fulvestrant Doubles PFS in HR+ Breast Cancer

December 7th 2016

The addition of everolimus (Afinitor) to fulvestrant (Faslodex) significantly improved progression-free survival rates in postmenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.

Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast Cancer

February 19th 2016

Benjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.

Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

February 3rd 2016

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer

January 29th 2016

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.